Clinical Trial Update: Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicates the Phase 1/Phase 2 study of alemtuzumab for multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: WITHDRAWN